Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
Ardine
M
M
Generali
D
D
Donadio
M
M
Bonardi
S
S
Scoletta
M
M
Vandone
A M
AM
Mozzati
M
M
Bertetto
O
O
Bottini
A
A
Dogliotti
L
L
Berruti
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D002118:Calcium / Q000097:blood / Q000633:toxicity*; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D010281:Parathyroid Hormone / Q000097:blood / Q000633:toxicity*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone; D002118:Calcium